Generation Bio Co (GBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Generation Bio Co (GBIO) has a cash flow conversion efficiency ratio of -1.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-52.68 Million) by net assets ($50.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Generation Bio Co stock valuation for the company's overall valuation and market capitalisation.
Generation Bio Co - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Generation Bio Co's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Generation Bio Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Generation Bio Co ranked by their cash flow conversion efficiency. See GBIO operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beaconsmind AG
PA:MLBMD
|
-1.608x |
|
PPAP Automotive Limited
NSE:PPAP
|
0.081x |
|
QT Imaging Holdings, Inc. Common Stock
NASDAQ:QTI
|
-2.154x |
|
5Th Planet Games A/S
OL:5PG
|
0.004x |
|
Total Soft Bank Ltd
KQ:045340
|
0.094x |
|
Bio-Works Technologies AB
ST:BIOWKS
|
-0.085x |
|
Cuhadaroglu Metal Sanayi ve Pazarlama AS
IS:CUSAN
|
0.946x |
|
Sunndal Sparebank
OL:SUNSB
|
N/A |
Annual Cash Flow Conversion Efficiency for Generation Bio Co (2018–2024)
The table below shows the annual cash flow conversion efficiency of Generation Bio Co from 2018 to 2024. View Generation Bio Co stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $86.20 Million | $-88.56 Million | -1.027x | -295.65% |
| 2023-12-31 | $203.13 Million | $-52.74 Million | -0.260x | +28.40% |
| 2022-12-31 | $282.49 Million | $-102.45 Million | -0.363x | -50.77% |
| 2021-12-31 | $381.75 Million | $-91.82 Million | -0.241x | +8.09% |
| 2020-12-31 | $268.01 Million | $-70.14 Million | -0.262x | -163.95% |
| 2019-12-31 | $-98.59 Million | $-40.35 Million | 0.409x | -39.47% |
| 2018-12-31 | $-41.59 Million | $-28.12 Million | 0.676x | -- |
About Generation Bio Co
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise me… Read more